Steven M Paul has bought stock on 5 days since Jan 2016

Dr. Steven M. Paul, M.D. is the Founder and Independent Chairman of Rapport Therapeutics, Inc. (RAPP), a clinical-stage biopharmaceutical company focused on developing small molecule medicines for central nervous system (CNS) disorders, including its lead candidate RAP-219 for focal epilepsy and other conditions.( As a director, he has recently engaged in insider trading activity, including acquiring 41,666 shares valued at approximately $1,027,111 and receiving 21,850 stock options on June 17, 2025.(

Dr. Paul brings over 40 years of R&D leadership in neuroscience, having co-founded companies such as Karuna Therapeutics, Sage Therapeutics, and Voyager Therapeutics, and currently serving as Chief Scientific Officer and President of R&D at Karuna while on the board of Sage.( His career includes 18 years at the National Institutes of Health as Scientific Director of the National Institute of Mental Health, followed by 17 years at Eli Lilly & Co., rising to Executive Vice President for Science and Technology and President of Lilly Research Laboratories.( He holds a bachelor’s in Biology and Psychology, M.S., and M.D. from Tulane University School of Medicine, and is a Professor of Psychiatry and Neurology at Washington University School of Medicine.(

Written by Perplexity from public sources.